Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;80(2):136-142.
doi: 10.4046/trd.2017.80.2.136. Epub 2017 Mar 31.

Response Evaluation of Chemotherapy for Lung Cancer

Ki-Eun Hwang  1 , Hak-Ryul Kim  1
Affiliations
Review

Response Evaluation of Chemotherapy for Lung Cancer

Ki-Eun Hwang et al. Tuberc Respir Dis (Seoul). 2017 Apr.

Abstract

Assessing response to therapy allows for prospective end point evaluation in clinical trials and serves as a guide to clinicians for making decisions. Recent prospective and randomized trials suggest the development of imaging techniques and introduction of new anti-cancer drugs. However, the revision of methods, or proposal of new methods to evaluate chemotherapeutic response, is not enough. This paper discusses the characteristics of the Response Evaluation Criteria In Solid Tumor (RECIST) version 1.1 suggested in 2009 and used widely by experts. It also contains information about possible dilemmas arising from the application of response assessment by the latest version of the response evaluation method, or recently introduced chemotherapeutic agents. Further data reveals the problems and limitations caused by applying the existing RECIST criteria to anti-cancer immune therapy, and the application of a new technique, immune related response criteria, for the response assessment of immune therapy. Lastly, the paper includes a newly developing response evaluation method and suggests its developmental direction.

Keywords: Drug Therapy; Evaluation Studies as Topic; Lung Neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: No potential conflict of interest relevant to this article was reported.

References

    1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214. - PubMed
    1. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33:533–537. - PubMed
    1. Therasse P. Measuring the clinical response: what does it mean? Eur J Cancer. 2002;38:1817–1823. - PubMed
    1. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91:523–528. - PubMed
    1. Prasad SR, Saini S, Sumner JE, Hahn PF, Sahani D, Boland GW. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr. 2003;27:380–384. - PubMed